

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

SECTION 1: IDENTIFICATION

Product name : Cefuroxime Formulation

Manufacturer or supplier's details

Company : MSD

Address : 91-105 Harpin Street
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Respiratory sensitisation : Category 1

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements :

Prevention:

P261 Avoid breathing mist or vapours.

P284 Wear respiratory protection.

Response:

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Disposal:

P501 Dispose of contents/ container to an approved waste

Cefuroxime Formulation

Version 2.2 Revision Date: 30.09.2023 SDS Number: 10844551-00004 Date of last issue: 04.04.2023
 Date of first issue: 06.09.2022

disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cefuroxime	55268-75-2	>= 1 -< 10

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
 If not breathing, give artificial respiration.
 If breathing is difficult, give oxygen.
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
 Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention if symptoms occur.
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause allergy or asthma symptoms or breathing difficulties if inhaled.
 Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire- : Exposure to combustion products may be a hazard to health.

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

fighting
Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Sulphur oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

Cefuroxime Formulation

Version 2.2 Revision Date: 30.09.2023 SDS Number: 10844551-00004 Date of last issue: 04.04.2023
 Date of first issue: 06.09.2022

- assessment
 Keep container tightly closed.
 Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
 Keep tightly closed.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cefuroxime	55268-75-2	TWA	100 µg/m ³ (OEB 2)	Internal
Further information: RSEN				

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Laboratory operations do not require special containment.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection : Chemical-resistant gloves
- Material

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Colour : white
off-white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n- : Not applicable

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

octanol/water
Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Cefuroxime:**

Acute oral toxicity : LD50 (Rat): > 10,000 mg/kg
LD50 (Mouse): > 10,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): > 4,000 mg/kg
Application Route: Intravenous
LD50 (Mouse): > 10,000 mg/kg
Application Route: Intravenous

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

LD50 (Rabbit): > 1,500 mg/kg
Application Route: Intravenous

LD50 (Dog): > 1,500 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:**Cefuroxime:**

Result : Sensitiser

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Cefuroxime:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Result: positive

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Cefuroxime Formulation

Version 2.2 Revision Date: 30.09.2023 SDS Number: 10844551-00004 Date of last issue: 04.04.2023
Date of first issue: 06.09.2022

Components:**Cefuroxime:**

Effects on fertility : Test Type: Fertility
Species: Mouse
Application Route: Oral
Fertility: NOAEL: 6,400 mg/kg body weight
Symptoms: No adverse effects

Test Type: Fertility
Species: Rabbit
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Symptoms: No adverse effects

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:**Cefuroxime:**

Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cefuroxime:**

Species : Rat
NOAEL : 900 mg/kg
Application Route : Subcutaneous
Exposure time : 3 M
Symptoms : No adverse effects

Species : Dog
NOAEL : 400 mg/kg
LOAEL : 1,600 mg/kg
Application Route : Oral
Exposure time : 27 W
Target Organs : Blood
Symptoms : Gastrointestinal disturbance

Species : Monkey
NOAEL : 450 mg/kg
Application Route : Subcutaneous
Exposure time : 1 M
Target Organs : Blood, Urinary tract
Remarks : May cause damage to organs.

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Cefuroxime:**

General Information	:	Repeated contact may cause allergic reactions in very susceptible persons.
Inhalation	:	Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis, Headache, Dizziness, dry mouth, Fatigue, constipation, colitis

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cefuroxime:****Ecotoxicology Assessment**

Acute aquatic toxicity	:	Toxic effects cannot be excluded
Chronic aquatic toxicity	:	Toxic effects cannot be excluded

Persistence and degradability

No data available

Bioaccumulative potential**Components:****Cefuroxime:**

Partition coefficient: n-octanol/water	:	log Pow: -0.429
--	---	-----------------

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable

IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

IMDG-Code

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Hazchem Code	:	Not applicable

Special precautions for user

Not applicable

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

Revision Date : 30.09.2023
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

AICC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect

Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.2	30.09.2023	10844551-00004	Date of first issue: 06.09.2022

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN